Skip directly to content

Our business units

Pfizer works across various different sectors within the UK pharmaceutical industry, including commercial, research and development (R&D), manufacturing, packaging and distribution.

To meet the needs of these diverse sectors, our business is divided into two distinct business units:

Pfizer Innovative Health (PIH) is committed to discovering, developing, manufacturing and delivering innovative products and vaccines that change the outcome of chronic conditions and devastating diseases.

The PIH portfolio in the UK includes:

  • Existing treatments and the development of new treatments in the following therapy areas:
    • Inflammation and immunology
    • Metabolic disease, cardiovascular risk & respiratory health
    • Neuroscience & pain
    • Oncology
    • Rare disease
    • Vaccines
  • Consumer healthcare, which develops, manufactures and markets leading over-the-counter medicines, vitamins and nutritional products

Pfizer Essential Health (PEH) is a large and highly diverse business that manages a vast portfolio of trusted, quality medicines at all stages of the product lifecycle from new launches to those which have or will go off patent in the near future, offering savings for the healthcare system.

The PEH portfolio in the UK includes medicines that treat patients for a variety of acute and chronic conditions across many therapeutic areas, including many critical medicines, sterile injectables and biosimilars:

  • Anti-infectives
  • Women's and Men's Health
  • Cardiovascular
  • Nervous System
  • Oncology

These two business units are underpinned by our Worldwide R&D and Global Supply divisions and the Enabling Functions that advance all of the company’s businesses, organisations and priorities (such as Corporate Affairs, Legal, HR and Business Technology).

PP-PFE-GBR-0596 / Sept 2017